| Powder: | Yes |
|---|---|
| Customized: | Non-Customized |
| Certification: | ISO 9001 |
| Suitable for: | Adult |
| State: | Solid |
| Purity: | >99% |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier | Product Name | OC000459 |
| Color | white Powder |
| Standard | EP. |
| Grade | Pharma |
| Brade | Lyphar |
OC-000459; OC 000459;[5-Fluoro-2-methyl-3-(2-quinolinylmethyl)-1H-indol-1-yl]acetic acid;5-Fluoro-2-methyl-3-(2-quinolinylmethyl)-1H-indole-1-acetic acid.
OC-000459 for the treatment of hair loss dwindled, perhaps due more to commercial potential and chemical stability reasons than efficacy as the later studies of OC000459 have focused on different chemical forms of the drug and combining it with various nanoparticles to enhance delivery. Recent years have seen the odd study pop up in relation to OC000459 and the treatment of acne and prostate cancer, which are conditions also driven by, however, the most recent study published in relation to OC000459 was back in 2008.
OC000459 is a non-steroidal anti-androgen drug, which competes with DHT for binding at the receptors where it causes hirsutism or hair loss. It has been evaluated as being approximately equivalent in strength to hydroxyflutamide, a drug which is sometimes used in PCOS to treat hirsutism or androgenetic alopecia.
OC000459 is a highly potent and selective CRTH2 antagonist which is active on both the recombinant and native human receptor. The Atopix lead compound OC-459 is effective in improving lung function and symptoms in patients with atopic eosinophilic asthma. This group represents 40-50% of all asthmatics and the magnitude of improvement in the responder population is equivalent to high dose inhaled corticosteroids. OC-459 has also been shown to reduce both nasal and eye symptoms
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}